Skip to main content
. 2015 Jun 19;6(27):23548–23560. doi: 10.18632/oncotarget.4556

Figure 1. Hyperglycemia decreases the cytotoxic effect of metformin.

Figure 1

A. DOV-13, Tyk-nu, and HeyA8 cells were treated with 0-10 mM metformin in normoglycemic (5.5 mM glucose) or hyperglycemic (25 mM glucose) conditions for 72 h and viability was measured using an MTT assay. Values are mean ± SEM, n ≥ 3. *p < 0.05 vs. same metformin concentration in 25 mM glucose. B. MTT viability assay of primary ovarian cancer cells treated with 0-10 mM metformin in normoglycemic (5.5 mM glucose) or hyperglycemic (25 mM glucose) conditions for 72 h. Values are mean ± SEM, n = 5 in one experiment. *p < 0.05 vs. same metformin concentration in 25 mM glucose. C. MTT assay of HeyA8 cells treated with 5 mM metformin for 72 h in the presence of increasing glucose concentrations (5.5-25 mM glucose). Values are mean ± SEM, n ≥ 3. *p < 0.05 vs. treatment in 5.5 mM glucose, ‡p < 0.05 vs. treatment in 10 mM glucose. D. MTT assay of HeyA8 cells cultured for 2 weeks in normoglycemic or hyperglycemic conditions and treated with 0-10 mM metformin for 72 h. Values are mean ± SEM, n = 3. *p < 0.05 vs. same metformin concentration in 25 mM glucose.